| Idea Name: |
Autoimmunity Treatment |
| Slogan: |
Monoclonal Antibody for Autoimmune Treatments |
| Supervisor Name: |
Dr. Maria Shabbir |
| Supervisor Designation: |
Associate Professor |
| Supervisor School: |
ASAB |
| Supervisor Department: |
Healthcare Biotechnology |
| Contact number: |
+92 334 5510903 |
| Email ID: |
[email protected] |
| Abstract: |
| KB312 is a first-in-class, selective, immune-cell depleting monoclonal antibody that targets activated immune cells with the goal of restoring equilibrium through immune tolerance induction. (Kira Biotech)
KB312 limits the negative impacts of broad immunosuppression and preserves beneficial immune cells that protect patients against infections and malignancies.
Anti CD 83 is also an important one |
| What is the unmet need in society that your idea will fulfill ? |
| Autoimmune diseases are considered to be the ones that are impossible to be cured. This is because they involves attack of body's own immune system towards itself. Such disease include Diabetes type 1, rheumatoid arthritis, myositis etc. If left untreated, these can further lead to cancer. |
| Who needs it ? How many would benefit ? |
| Any individual who is suffering from an autoimmune disease e.g.,
Type 1 Diabetes, Multiple Sclerosis, Rheumatoid arthritis, Myositis, lupus, Crohn's disease, psoriasis, scleroderma, and many more which also includes cancer as they further lead to it. |
| How will the solution works |
| Leads to the depletion of activated dendritic cells involved in the autoimmune disease. |
| Who are your competitors ? How is your solution different |
| Other treatments for such diseases include broad suppression if whole immune system which can lead to a number of problems on tge top of which include high risk of disease susceptibility. This treatment on the other hand is very effective and long term. |
| Status: |
new |
| Entry Date & Time: |
2022-12-17 (1306) |
